ACOR - アコ―ダ・セラピュ―ティクス (Acorda Therapeutics Inc.) アコ―ダ・セラピュ―ティクス



symbol ACOR
会社名 Acorda Therapeutics Inc (アコ―ダ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アコーダ・セラピューティクス(Acorda Therapeutics Inc.)はバイオ医薬品会社である。同社は神経障害患者を治療する療法の開発に従事する。同社は多発性硬化症(MS)患者の歩行を改善するための10ミリグラム(mg)のAmpyra(dalfampridine)延長放出錠剤を含む3件の米国食品医薬品局(FDA)承認治療薬を販売する。同社はまたZanaflexカプセルとタブレット、痙縮の管理のための短時間作用型の薬であるアメリカ食品医薬品局(FDA)認可薬及び帯状疱疹後神経痛関連の神経障害性疼痛の管理向けのFDA認可皮膚パッチであるQutenzaを販売する。同社はパーキンソン病、偏頭痛、多発性硬化症(MS)等の各種疾患を治療する神経療法のパイプラインを有する。同社の製品候補はレボドパの自己投与吸入用治療製剤であるCVT-301である。   アコ―ダ・セラピュ―ティクスは、米国のバイオ医薬品販売会社。多発性硬化症や脊髄損傷、および神経系の他の疾患の神経機能を改善する新しい治療法の開発および商業化を行う。また、チザニジン塩酸塩を含む「ザナフレックス」錠を販売する。本社は、ニューヨーク州ア―ズリ―。   
本社所在地 420 Saw Mill River Road Ardsley NY 10502 USA
代表者氏名 Ron Cohen ロン・コーエン
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 914-347-4300
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 484人
EBITDA EBITDA(百万ドル) 167.04000
終値(lastsale) 17.65
時価総額(marketcap) 838089299.45
時価総額 時価総額(百万ドル) 776.83520
売上高 売上高(百万ドル) 588.93000
企業価値(EV) 企業価値(EV)(百万ドル) 724.12520
当期純利益 当期純利益(百万ドル) -145.06100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acorda Therapeutics Inc revenues increased less than 1% to $259.5M. Net income totaled $38M vs. loss of $27.1M. Revenues reflect Net product revenues increase of 3% to $253.4M also reflect License revenue decrease from $6.7M to $0K Royalty revenues decrease of 11% to $6.1M. Net income reflects Research and development - decrease of 40% to $54.8M (expense).



   Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results  2021/03/04 21:01:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
   Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021  2021/02/25 12:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
   Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent  2021/02/11 12:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
   FXNEWS24 |Acorda (ACOR) to Report This autumn Earnings: What's within the Playing cards? | UK Forex Reviews  2021/02/08 18:54:10 FXNews24
Acorda (ACOR) to Report This autumn Earnings: What's within the Playing cards? | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Acorda Stock at $35 a Share? This Analyst Thinks It’s Possible  2021/01/16 01:19:58 Yahoo Finance
It's been a stellar week for Acorda Therapeutics (ACOR) investors. The stock skyrocketed over 60% after the company announced it is selling its manufacturing operations for Inbrija - Acorda’s FDA approved treatment of OFF episodes in Parkinson's disease - which should also reduce its headcount by 16%. The company’s 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, is being sold off to Catalent, along with the facility’s employees. The net proceeds from the deal will pocket the company approximately $70 million in cash and will reduce its annual operation costs by $40 million. Along with a recent at-the-market offering, the sale provides enough cash for the coffers to swing the cash balance back into the green, says Cowen analyst Phil Nadeau. The analyst believes this resolves a major investor concern. “The key risk facing ACOR investors is the ability of the company to sufficiently fund operations in order to successfully launch Inbrija and achieve cash flow breakeven without meaningful dilution,” the 5-star analyst said. “The sale of ACOR's manufacturing operations, restructuring, and disclosure of strong Q4 Inbrija sales meaningfully increase the likelihood that Acorda's balance sheet is sufficiently strong to support operations back to profitability, in our opinion." In addition to the restructuring, Acorda also offered a glimpse of Q4 financial results.
   Primary Sclerosing Cholangitis Market To 2026 Anticipated To Experience Extraordinary Growth During Forecast Period | Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM BioPharmaceuticals (US)  2020/11/06 15:58:36 OpenPR
Primary Sclerosing Cholangitis Market research report is formulated with the exact understanding of customer requirements. Market status at the global and regional level about Primary Sclerosing Cholangitis industry is offered through this report which helps gain business insights at the
   Acorda Reports Third Quarter 2020 Financial Results  2020/11/03 21:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the third quarter ended September 30, 2020. “We are encouraged by the 24% increase in INBRIJA net sales over the second quarter, even with the challenges posed by the second wave of COVID-19. We are also pleased that coverage for INBRIJA continued to increase during the quarter, with over 96% of commercially-insured patients now having access to it,” said Ron Cohen, M.D., Acorda's Pr
   Acorda Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/11/03 18:25:00 Stock Market Daily
Acorda Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020  2020/10/27 11:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET. To participate in the Webcast/Conference call, please note there is a new pre-registration process. To register for the Webcast/Conference Call, use the link below: **When registering please type your phone number wit
   Acorda Therapeutics (NASDAQ:ACOR) Rating Lowered to Sell at Zacks Investment Research  2020/10/25 06:08:41 Transcript Daily
Zacks Investment Research lowered shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a research note published on Wednesday, reports. According to Zacks, “Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson’s disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological […]
   Acorda Therapeutics, Inc. (NASDAQ:ACOR) Sees Large Growth in Short Interest  2020/10/20 11:37:06 Zolmax News
Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 12,600,000 shares, an increase of 24.9% from the September 15th total of 10,090,000 shares. Approximately 26.7% of the company’s stock are short sold. Based on an average daily trading volume, […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era | AbbVie, AcelRx Pharma, Acorda Therapeutics  2020/10/01 15:01:15 OpenPR
The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax  2020/09/03 11:55:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アコ―ダ・セラピュ―ティクス ACOR Acorda Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)